President elect Donald Trump has said he will bring drug manufacturing back to the US and introduce bidding measures to cut the amount the country spends on medicines.
If even the apparently non-joke, potential US presidential candidate Donald Trump criticizes your behaviour, you must know what you are doing is unpopular.
Pharma needs to learn from other sectors and abandon the multistage development paradigm in favour of a two-stage design and manufacturing model to cut attrition rates.
Pfizer’s $68bn swoop for Wyeth looks set to start an epidemic of merger madness according to comments by Frost & Sullivan (F&S) analyst Shabeer Hussain.
Efforts by Pakistan to build a pharmaceutical sector to rival that
of neighbouring India are being undermined by regulatory
interference, according to representatives of the domestic drug
industry.
The news that US President George Bush will be residing at the
White House for a further four years has been greeted with some
measure of relief by the pharmaceutical industry, which had been
worried about drug price curbs in the...
